Serum level of cytokine IL-30 in psoriatic patients and correlation with disease severity.

Psoriasis is a common chronic immune-mediated inflammatory skin disorder characterized by erythematous silvery scaling of the skin and associated severe itching. Reports indicate that psoriasis is affecting about 2% of the world population and life quality in a way that limits the patient activity and thereby productivity in a community. Therefore, determining appropriate therapeutics for psoriasis would make a difference in the lives of the patients and their communities. To address this, scientists have been working on different biological agents, such as interleukins and their antagonists, to regulate the common inflammatory process in psoriasis. For the current research project, serum was collected from 26 psoriatic patients and another 26 health controls, and the serums were examined for the level of IL-30 to determine differences among the tested groups and to investigate a possible correlation between IL-30 and psoriasis area severity index (PASI). The study delineated differences of the IL-30 among the groups and a positive correlation between IL-30 and PASI among the psoriatic cases, which insights a need for further studies that include a large scale of participants to fully elucidate the involvement of IL-30 in psoriasis.